USE OF TARGETED DRUGS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA IN CHILDREN
Keywords:
acute myeloid leukemia, targeted therapy, chemotherapy, children, CD33Abstract
Current polychemotherapy for acute myeloid leukemia (AML) has reached its limit, achieving complete remission in 73% of patients with AML. Due to high toxicity and the risk of life-threatening complications, further intensification of chemotherapy regimens is impossible. Improving programmatic therapy for AML relies on the clinical application of advances in molecular biology, immunology, and tumor cell cytogenetics. Fundamental research in oncology has enabled the identification of the main stages of leukemia and the development of targeted (molecularly directed) treatments for AML.
References
Махачева Ф.А., Валиев Т.Т. Лечение острых миелоидных лейкозов у детей: современный взгляд на проблему. Онкогематология 2020;15(1):31-48. doi: 10.17650/1818-8346-2020-15-1-00-00. [Makhacheva F.A., Valiev T.T. Pediatric acute myeloid leukemias treatment: current scientific view. Onkogematologiya = Oncohematology 2020;15(1):31-48. (In Russ.)].
Rasche M., Zimmermann M., Borschel L., Bourquin J.P., Dworzak M., Klingebiel T., Lehrnbecher T., Creutzig U., Klusmann J.H., Reinhardt D. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 2018;32(10):2167-77. doi: 10.1038/s41375-018-0071-7.
Bolouri H., Farrar J.E., Triche T. Jr, Ries R.E., Lim E.L., Alonzo T.A., Ma Y., Moore R., Mungall A.J., Marra M.A., Zhang J., Ma X., Liu Y., Liu Y., Auvil J., Davidsen T.M., Gesuwan P., Hermida L.C., Salhia B., Capone S., Meshinchi S. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 2018;24:103-12. doi: 10.1038/nm.4439.
Chen J., Glasser C.L. New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML). Children 2020;7(2):12. doi: 10.3390/children7020012.
Gamis A.S., Alonzo T.A., Meshinchi S., Sung L., Gerbing R.B., Raimondi S.C., Hirsch B.A., Kahwash S.B., Heerema-McKenney A., Winter L., Glick K., Davies S.M., Byron P., Smith F.O., Aplenc R. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III
Walter R.B. Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Investig Drugs 2018;27:339-48. doi: 10.1080/13543784.2018.1452911.
Children's Oncology Group trial AAML0531. J Clin Oncol 2014;32(27):3021-32. doi: 10.1200/jc0.2014.55.3628.
L.S.Makhmonov., F.Kh.Mamatkulova., M.B. Berdiyarova, K.E. Shomurodov.THE MAIN CAUSES OF ANEMIA IN IRON AND VITAMIN B 12 DEFICIENCY ASSOCIATED WITH HELICOBACTER PYLORI
Makhmonov L. S., Mamatkulova F. Kh., Kholturaeva D. F., Muyiddinov Z. Z. IMPORTANCE OF DETECTION OF HEPSIDINE AND INTERLEUKINS IN "Science and Education" Scientific Journal / Impact Factor 3,848 (SJIF) February 2023 / Volume 4 Issue 2.
Mamatkulova Feruza Khaydarovna, Akhmedov Husan Isrofilovich, Abdiev Kattabek Makhmatovich. Essential Thrombocythemia - Principal Analysis in Children and Adolescents. JOURNAL OF INTELLECTUAL PROPERTY AND HUMAN RIGHTS Volume: 2 Issue: 10 | Oct – 2023 ISSN: 2720-6882. 23-29.
Mamatkulova F. X. Mamatova N. T. Ruziboeva.O. N. Prevention Of Anemia In Patients With Tuberculosis. The American Journal of Medical Sciences and PharmaceuticalResearch,2(11),62–65.
Norsworthy K.J., Ko C.W., Lee J.E., Liu J., John C.S., Przepiorka D., Farrell A.T., Pazdur R. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. Oncologist 2018;23(9):1103-8.
doi: 10.1634/theoncologist.2017-0604.
Mercher T., Schwaller J. Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention. Front Pediatr 2019;7:401. doi:10.3389/fped.2019.00401.
